Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania

项目摘要/摘要 申请加州大学新的全球传染病研究培训项目(GIDRTP) 弗吉尼亚州(UVA)在贫困和传染病方面对全球领导者进行了数十年的培训，通过 支持新发传染病国际培训和研究的周期，建立行动 能力、少数民族健康国际研究培训和Fogarty GIDRTP。这些先前的经验 提供经验教训和经过测试的机制，将受训人员培养成独立的公共卫生人员 科学家。尽管之前的重点是早期实习生，如本科生、硕士或博士生， 我们注意到，在坦桑尼亚，通过博士后培训发展到研究领导力的独特障碍。 我们在2021年对坦桑尼亚博士后科学家进行了需求评估，证实了这一点 并概述了构建以博士后为重点的GIDRTP的差距和机会。UVA， 传染病和国际卫生司和全球卫生公平中心 几十年来一直处于营养不良及其传染性后果研究和培训的前沿。在非- 在大流行期间，结核病是一种可治愈的传染病的头号杀手。新冠肺炎进一步提升了 扰乱了结核病护理，预计在未来五年内死于结核病的人数将增加20%。营养不良， 营养不良和营养不良都会导致糖尿病等疾病，这是最重要的驱动因素 在全球范围内结核病的发病率。因此，GIDRTP旨在加强现有的教育和研究联系 与UVA和乞力马扎罗基督教医科大学学院/乞力马扎罗临床研究所合作 (KCMUCo/KCRI)在坦桑尼亚，支持坦桑尼亚博士后实习生成长为研究带头人 在营养不良和结核病的交叉点。 我们的目标是通过一项个性化的研究，培养6名博士后科学家，每人支持3年。 基于《非洲研究领导力之路》报告框架的领导力计划(2020年)。此外 为了将博士后研究员与坦桑尼亚和弗吉尼亚大学的导师相匹配，个性化的研究领导计划将 包括由主要教育工作者和核心方案教员进行评估，包括一名生物统计学家进行设计 针对研究团队管理的公制类别的个性化课程工作和技能建设， 沟通、拨款撰写、专业精神和职业轨迹。我们将利用现有的基础设施 来自美国国立卫生研究院、比尔和梅林达·盖茨基金会、欧洲和发展中国家的资金 国家试验伙伴关系，世界卫生组织和丹麦外交部结核病和 在坦桑尼亚进行营养不良研究，我们希望启动初级科学家和内容负责人的职业生涯 他们将竞争独立的资金，制定研究议程，制定政策，并在- 符合世界卫生组织的遏制结核病战略。

PROJECT SUMMARY / ABSTRACT This application for a new Global Infectious Diseases Research Training program (GIDRTP) at the University of Virginia (UVA) extends decades of training global leaders in diseases of poverty and infectious diseases through cycles of support of International Training and Research in Emerging Infectious Diseases, Actions for Building Capacity, Minority Health International Research Training, and Fogarty GIDRTPs. These prior experiences provide lessons learned and tested mechanisms for developing trainees into independent public health scientists. Despite the prior focus on early stage trainees such as undergraduate, Masters or doctoral students, we have noted unique barriers in progression through postdoctoral training to research leadership in Tanzania. We performed a needs assessment among Tanzanian postdoctoral scientists in 2021 which confirmed this observation and outlined gaps and opportunities with which to structure a postdoctoral focused GIDRTP. UVA, the Division of Infectious Diseases and International Health, and the Center for Global Health Equity have been at the forefront of research and training in malnutrition and its infectious consequences for decades. In non- pandemic periods, tuberculosis (TB) is the leading killer from a curable infectious disease. COVID-19 has further disrupted TB care and is projected to increase deaths from TB by 20% over the next five years. Malnutrition, both undernutrition and poor nutrition leading to conditions such as diabetes mellitus, is the most important driver of TB disease globally. Therefore, this GIDRTP aims to strengthen existing educational and research linkages with the UVA and the Kilimanjaro Christian Medical University College/ Kilimanjaro Clinical Research Institute (KCMUCo/KCRI) in Tanzania, to support Tanzanian postdoctoral trainees' growth to research leaders working at the intersection of malnutrition and TB. We aim to train 6 postdoctoral scientists with 3 years of support each through an individualized research leadership plan based on the framework of the Path to Research Leadership in Africa Report (2020). In addition to matching postdoctoral fellows to Tanzanian and UVA mentors, the individualized research leadership plan will include assessment by Lead Educators and core programmatic faculty including a biostatistician to design personalized coursework and skills building toward the metric categories of research team management, communication, grant writing, professionalism and career trajectory. We will harness the current infrastructure of funding from the National Institutes of Health, Bill and Melinda Gates Foundation, European and Developing Countries Trials Partnership, World Health Organization and the Danish Ministry of Foreign Affairs for TB and malnutrition research in Tanzania, and we expect to launch the careers of junior scientists and content leaders that will compete for independent funding, set research agendas, make policy and benefit their communities in- line with the World Health Organization's End TB Strategy.